Trial Profile
Anti Inflammatory Lipid Mediators in Asthma: A Double Blind Placebo Control Cross Over, Proof of Concept Study of CXA-10 to Reduce Bronchial Hyperresponsiveness in Obese Asthmatics; Lipid Anti-Inflammatory Mediators in Asthma to Reduce Hyperresponsiveness in Obese Asthmatics
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Mar 2024
Price :
$35
*
At a glance
- Drugs IMR-261 (Primary)
- Indications Asthma
- Focus Proof of concept; Therapeutic Use
- Acronyms ALMA; LIMA
- 29 Feb 2024 Planned End Date changed from 30 Jan 2029 to 30 Jan 2030.
- 29 Feb 2024 Planned primary completion date changed from 30 Nov 2028 to 30 Nov 2029.
- 01 Mar 2023 Planned End Date changed from 1 Jan 2029 to 30 Jan 2029.